EPO

Buy EPO Peptide For Sale: High-Purity Research Erythropoietin

Looking for buy EPO peptide for sale? Sino Research Peptide Manufacturer supplies EPO 3000iu (Erythropoietin) at 3000 international units (IU) in lyophilised format, at >99% purity (HPLC verified), for in vitro and pre-clinical laboratory research use only. Erythropoietin (EPO) ranks among the most extensively researched glycoprotein hormones in biomedical science, with a published literature base encompassing erythropoiesis, neuroprotection, cardioprotection, regenerative medicine, and mesenchymal stem cell biology across more than 180 independent pre-clinical studies. Below, you’ll find a full research overview of this glycoprotein hormone, along with everything you need to know before you buy EPO peptide online.

What Is EPO (Erythropoietin)?

Erythropoietin (EPO) is a glycoprotein cytokine and the principal endogenous regulator of erythropoiesis — the physiological process by which erythroid progenitor cells in the bone marrow differentiate and mature into circulating red blood cells. Mature human EPO consists of 165 amino acids, following cleavage of a 27-amino acid N-terminal signal peptide from the 193-amino acid precursor, and is heavily glycosylated, with carbohydrate chains accounting for approximately 40% of its molecular weight. Buy EPO Peptide For Sale above $500 from Sino Research Peptide Manufacturer and get a free shipping.

The body produces EPO endogenously in the peritubular interstitial cells of the kidneys in response to hypoxic conditions, with the hypoxia-inducible transcription factor (HIF) pathway serving as the primary molecular switch governing EPO gene expression. Under hypoxic stress, HIF-1α and HIF-2α escape prolyl hydroxylase-mediated degradation, translocate to the nucleus, and upregulate EPO transcription — a pathway that has itself become a major area of pharmaceutical research through HIF-stabiliser compounds. The best place to Buy EPO Peptide For Sale online is from Sino Research Peptide Manufacturer

Beyond Erythropoiesis: A Dual-Receptor Profile

Recombinant human EPO (rhEPO) has been documented to signal through both the classical homodimeric EPOR and a proposed heterodimeric receptor complex comprising EPOR and CD131 (the common β-subunit of cytokine receptors for IL-3, IL-5, and GM-CSF). Researchers believe it’s through this heterodimeric receptor that EPO exerts its pleiotropic, non-haematopoietic tissue-protective effects — including neuroprotection, cardioprotection, and modulation of mesenchymal stem cell differentiation — in brain, heart, and skeletal muscle tissue in pre-clinical models.

Chemical and Research Specifications

How Does EPO Work in Research?

In laboratory and pre-clinical research settings, researchers study recombinant human EPO (rhEPO) across multiple biological systems, owing to its dual receptor engagement profile and its role as both a haematopoietic growth factor and a pleiotropic tissue-protective cytokine. Its standardised IU-based dosing makes it well suited for reproducible, quantitative in vitro assays and dose-response studies.

When EPO binds the homodimeric EPOR on erythroid progenitor cells, it initiates receptor dimerisation and activation of JAK2 kinase, which phosphorylates STAT5. Activated STAT5 translocates to the nucleus to drive transcription of genes promoting cell survival, proliferation, and differentiation along the erythroid lineage — inhibiting apoptosis of erythroid progenitors through upregulation of anti-apoptotic proteins including Bcl-xL. Parallel activation of PI3K/Akt and MAPK/ERK signalling cascades further supports progenitor cell survival and mitogenesis.

Via the heterodimeric EPOR/CD131 complex, EPO research has documented non-erythropoietic effects in brain, heart, and skeletal muscle tissue in pre-clinical models, including neuronal survival under hypoxic/ischaemic stress, attenuation of inflammatory mediators, promotion of angiogenesis, and support for mesenchymal stem cell osteogenic and endothelial transdifferentiation. The 3000 IU formulation allows researchers to prepare a wide range of research concentrations for standardised pathway and receptor studies.

EPO Peptide Benefits: Key Research Areas

• EPOR homodimer receptor-binding, JAK2/STAT5 phosphorylation, and downstream erythropoiesis pathway studies
• EPOR/CD131 heterodimer tissue-protective signalling research
• PI3K/Akt and MAPK/ERK anti-apoptotic signalling cascade investigations
• Erythroid progenitor cell survival, proliferation, and differentiation assays
• Neuroprotection and neurodegeneration pathway studies in pre-clinical models
• Cardioprotection and ischaemia-reperfusion pathway research
• Mesenchymal stem cell (MSC) osteogenic and endothelial transdifferentiation studies
• HIF pathway and hypoxia-inducible erythropoietin gene regulation research
• Angiogenesis and bone remodelling pathway investigations
• Comparative erythropoiesis-stimulating agent (ESA) research — epoetin vs. darbepoetin vs. CERA

What Do Studies Say About EPO?

EPO carries one of the most extensive and well-established research literature bases of any recombinant protein compound in biomedical science, with published evidence spanning erythropoiesis biology, neuroprotection, cardioprotection, regenerative medicine, and stem cell research.

Comprehensive Neuroprotection Review: 180+ Pre-Clinical Studies

A landmark review summarised more than 12 years of pre-clinical and clinical EPO neuroprotection research, covering studies performed by independent research groups worldwide. The review documented that almost all of the more than 180 pre-clinical studies conducted over this period yielded positive results for EPO as a neuroprotective compound, across indications including stroke, traumatic brain injury, spinal cord injury, neurodegeneration, and psychiatric disorders. Early clinical trials produced positive and stimulating results, and the authors described EPO as a highly attractive candidate for neuroprotection/neuroregeneration research, noting its safety record from decades of approved erythropoietic use and its documented ability to cross the blood-brain barrier in pre-clinical models.

Reference: Ehrenreich H et al. (2011). Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Practice & Research Clinical Anaesthesiology. PubMed PMID: 21619868.

EPO Physiology, Pharmacology, and Receptor Review

A comprehensive review of EPO’s physiology and pharmacology documented characterisation of the homodimeric EPOR and its signalling through protein kinases, anti-apoptotic proteins, and transcription factors. The review confirmed EPO exerts pleiotropic effects via the heterodimeric EPOR/CD131 complex in non-haematopoietic tissues, and reviewed EPO derivatives with prolonged half-life — including darbepoetin alfa and methoxy PEG-epoetin beta — alongside EPO mimetic peptides, HIF stabilisers, and EPO gene transfer approaches. The review confirmed the in vivo bioassay standard: one international unit (IU) produces the same erythropoietic response in animals as 5 μmol cobalt chloride.

Reference: Jelkmann W (2013). Physiology and Pharmacology of Erythropoietin. Transfusion Medicine and Hemotherapy. PMC Article PMC3822280.

EPO as a Key Regulator of Erythropoiesis, Bone Remodelling, and MSC Biology

A detailed review examined EPO’s broader roles beyond erythropoiesis, focusing on its functions as a regulator of bone remodelling and endothelial transdifferentiation of multipotent mesenchymal stem cells (MSCs). The review documented that EPO signals through EPOR/CD131 in brain, heart, and skeletal muscle tissue to produce tissue-protective effects, and confirmed EPO induces osteogenic and endothelial transdifferentiation of MSCs via EPOR signalling, leading to bone remodelling, induction of angiogenesis, and secretion of trophic factors.

Reference: Papadaki HA et al. (2021). Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine. International Journal of Molecular Sciences. PMC Article PMC8391952.

EPO Neuroprotective Peptide Derivatives Review

A focused review examined the development of EPO-derived peptides and non-erythropoietic EPO analogues for neuroprotection research. The review documented accumulated evidence for EPO’s neuroprotective effects in pre-clinical models of acute and chronic degenerative disorders, while identifying limitations of full-length EPO for this research application — specifically thromboembolic risk and erythrocytosis when applied at neuroprotective doses. The authors reviewed EPO mimetic peptides (EMPs) as research alternatives, noting their high potency, selectivity, and reduced immunogenicity as favourable properties for in vitro and pre-clinical pathway studies.

Reference: Ghasemi M et al. (2018). Peptide Derivatives of Erythropoietin in the Treatment of Neuroinflammation and Neurodegeneration. Neurochemical Research. PubMed PMID: 29680240.

A Century of EPO Research: Receptor Characterisation and HIF Pathway

A landmark review marking a century of EPO research summarised major advances in understanding EPO gene regulation, particularly the identification of hypoxia-inducible transcription factors (HIF-1α and HIF-2α) regulated by prolyl hydroxylase dioxygenases as the primary molecular switch for EPO expression. The review confirmed characterisation of the homodimeric EPOR and its signalling through JAK2/STAT5, and confirmed that EPOR expression in non-haematopoietic tissues indicates EPO functions as a pleiotropic viability and growth factor.

Reference: Jelkmann W (2007). Erythropoietin after a century of research: younger than ever. European Journal of Haematology. PubMed PMID: 17253966.

Product Specifications

Suitable Laboratory Uses for EPO 3000iu

• EPOR homodimer receptor-binding assays and JAK2/STAT5 phosphorylation studies
• EPOR/CD131 heterodimer tissue-protective pathway research
• Erythroid progenitor cell proliferation, survival, and differentiation assays in vitro
• PI3K/Akt and MAPK/ERK signalling cascade investigations
• Neuroprotection pathway studies under hypoxic or oxidative stress conditions
• Cardioprotection and ischaemia-reperfusion injury pathway research
• MSC osteogenic and endothelial transdifferentiation studies
• HIF pathway regulation and hypoxia-inducible gene expression research
• Dose-response and comparative ESA research — standardised IU format

Where to Buy EPO Peptide Online / Buy EPO Peptide For Sale

Where to Buy EPO Peptide / Best place to Buy EPO Peptide For Sale

If you’ve been searching for where to buy EPO peptide, Sino Research Peptide Manufacturer offers a straightforward path to reliable, research-grade material. Every batch ships with purity verification, so you always know exactly what you’re working with. Wondering how to buy EPO peptide? Our streamlined ordering process gets research-grade material to your lab quickly, with fast, tracked dispatch to laboratories and institutions.

Buy EPO For Sale Online

Sino Research Peptide Manufacturer is a trusted supplier of research-grade peptides and recombinant proteins. All products ship in lyophilised format with batch-verified purity documentation. Whether you’re searching for EPO for sale online or the cheapest place to buy EPO without compromising on purity, we provide consistent quality with rigorous third-party analysis on every batch.

The standardised 3000 IU format aligns with established reference preparation standards used in pre-clinical and comparative ESA research, making it well suited for both single-concentration pathway studies and multi-point dose-response experiments.

Important Notice & Research Disclaimer

This product is supplied by Sino Research Peptide Manufacturer strictly for laboratory research use only. EPO 3000iu (Erythropoietin) as distributed by Sino Research Peptide Manufacturer is not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment. This compound is handled exclusively in controlled research settings for in vitro and pre-clinical studies.

Handling must only be performed by qualified and trained laboratory professionals in accordance with applicable regulations and institutional guidelines. Sino Research Peptide Manufacturer accepts no liability for any use of this compound outside of its intended laboratory research purpose. References to clinical trials and published research throughout this description are provided for informational and research context only and do not constitute medical claims or endorsements of any therapeutic application of this product.

.

References:

1. Husein el Hadmed, H., & Castillo, R. F. (2016). Buy EPO Peptide For Sale Cosmeceuticals: peptides, proteins, and growth factors. Journal of cosmetic dermatology, 15(4), 514-519. Buy EPO Peptide For Sale
2. Lupo, M. P., & Cole, A. L. (2007). Cosmeceutical peptides. Dermatologic therapy, 20(5), 343-349.Buy EPO Peptide For Sale
3. Gorouhi, F., & Maibach, H. I. (2009). Role of peptides in preventing or treating aged skin. International journal of cosmetic science, 31(5), 327-345.Buy EPO Peptide For Sale
4. Satriyasa B. K. (2019). Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clinical, cosmetic and investigational dermatology, 12, 223–228. https://doi.org/10.2147/CCID.S202919
5. Kalandakanond, S., & Coffield, J. A. (2001). Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. The Journal of pharmacology and experimental therapeutics, 296(3), 980–986. Buy EPO Peptide For Sale
6. Bakheit A. M. (2006). The possible adverse effects of intramuscular botulinum toxin injections and their management. Current drug safety, Buy EPO Peptide For Sale 1(3), 271–279. https://doi.org/10.2174/157488606777934431
7. Witmanowski, H., & Błochowiak, K. (2020). The whole truth about botulinum toxin – a review. Postepy dermatologii i alergologii, Buy EPO Peptide For Sale 37(6), 853–861. https://doi.org/10.5114/ada.2019.82795
8. Reddy, B. Y., Jow, T., & Hantash, B. M. (2012). Bioactive oligopeptides in dermatology: Part II. Experimental dermatology, 21(8), 569-575. Buy EPO Peptide For Sale
9. Miller, D. M., DeSilva, D., Pickart, L., & Aust, S. D. (1990).Buy EPO Peptide For Sale  Effects of glycyl-histidyl-lysyl chelated Cu(II) on ferritin dependent lipid peroxidation. Advances in experimental medicine and biology, 264, 79–84. https://doi.org/10.1007/978-1-4684-5730-8_11
10. Park, J. R., Lee, H., Kim, S. I., & Yang, S. R. Buy EPO Peptide For Sale  (2016). The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget, 7(36), 58405–58417. https://doi.org/10.18632/oncotarget.11168
11. Zhang, Q., Yan, L., Lu, J., & Zhou, X. (2022). Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in molecular biosciences, 9, 925700 Buy EPO Peptide For Sale . https://doi.org/10.3389/fmolb.2022.925700
12. Sakuma, S., Ishimura, M., Yuba, Y., Itoh, Y., & Fujimoto, Y. (2018). The peptide glycyl-ʟ-histidyl-ʟ-lysine is an endogenous antioxidant in living organisms, possibly by diminishing hydroxyl and peroxyl radicals. International journal of physiology, pathophysiology and pharmacology, 10(3), 132–138. Buy EPO Peptide For Sale
13. Leyden J., Stephens T., Finkey M., Appa Y., Barkovic S. Skin care benefits of copper peptide containing facial cream. Proceedings of the American Academy of Dermatology Meeting; February 2002; New York, NY, USA. Buy EPO Peptide For Sale
14. Leyden J., Stephens T., Finkey M., Barkovic S. Skin Care Benefits of Copper Peptide Containing Eye Creams. University of Pennsylvania; 2002. Buy EPO Peptide For Sale
15. Finkley M., Appa Y., Bhandarkar S. Copper peptide and skin. In: Elsner P., Maibach H., editors. Cosmeceuticals and Active Cosmetics: Drugs vs. Cosmetics. New York, NY, USA: Marcel Dekker; 2005. pp. 549–563. Buy EPO Peptide For Sale